FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:445-446 August 10, 2000 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Many pregnant women have nausea and vomiting during the first trimester; these effects may be severe and in some women they continue beyond the first trimester.¹ The cause is likely to be multifactorial, and the disorder is a diagnosis of exclusion.² Since the thalidomide tragedy, there is heightened awareness of the risks of drug therapy during pregnancy in general and of antiemetic therapy in particular.³ Although not licensed for nausea and vomiting of pregnancy, metoclopramide is the antiemetic drug of choice in pregnancy in several European countries.⁴ There have, however, been no prospective studies of the fetal . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Matok, I., Gorodischer, R., Koren, G., Sheiner, E., Wiznitzer, A., Levy, A. (2009). The Safety of Metoclopramide Use in the First Trimester of Pregnancy. NEJM 360: 2528-2535 [Abstract] [Full Text]